Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492160 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms
A Phase 2 study, sponsored by Maimonides Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 348
- Enrollment target
NCT07492160: Recruiting Phase 2 study, sponsored by Maimonides Medical Center.
NCT07492160 is a Phase 2 study that is actively recruiting participants, run by Maimonides Medical Center. The registered enrollment target is 348 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07492160, a Phase 2 study, is actively recruiting participants, sponsored by Maimonides Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 348 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are: Does cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss? Does cabergoline reduce the severity of breast symptoms and associated bother compared with placebo? Researchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss. Participants will: Complete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure Receive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure Complete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother A subset of participants will provide blood samples at selected time points to measure serum prolactin levels
Primary Outcome
The proportion of participants reporting any breast symptoms, including breast engorgement, milk leakage, tenderness, or need for pain relief, assessed using the Bristol Breast Symptoms Inventory.
Interventions
- DRUG Placebo
- DRUG Cabergoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What NCT07492160 shows while recruiting
NCT07492160 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07492160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07492160 about?
NCT07492160 is a clinical study titled "Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms". The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are: Does cabergoline decrease ...
What is the current status of trial NCT07492160?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 348 participants. The study started on 2026-03-16. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07492160?
The interventions under investigation include: Placebo (DRUG), Cabergoline (DRUG).
Who is sponsoring clinical trial NCT07492160?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07492160's enrollment target sits among peer trials
348 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI